Comparison · NCT02979899-69e3a058
TRC105 + Votrient vs Votrient: Overall Survival of Patients With Unresectable Angiosarcoma
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TRC105 + Votrient vs Votrient: Overall Survival of Patients With Unresectable Angiosarcoma. Trial comparisons, record NCT02979899-69e3a058. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02979899-69e3a058
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.274 | 0.179 | 0.396 | wilson | |
| Risk in group 2 | 0.311 | 0.209 | 0.436 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0373 | -0.194 | 0.122 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.88 | 0.508 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 0.835 | 0.384 | 1.82 | log | |
| Number needed to treat, for one fewer participant with the outcome on TRC105 + Votrient than on Votrient | 26.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TRC105 + Votrient | Weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily~TRC105: TRC105 antibody~Votrient: pazopanib | 17 | 62 | OG000 |
| Group 2 | Votrient | Standard dose votrient by mouth, once daily~Votrient: pazopanib | 19 | 61 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Survival of Patients With Unresectable Angiosarcoma
- Description
- Overall survival is the number of death events at 25 months, including all on-study and off-study deaths (past post-treatment 28-day follow up visit)
- Time frame
- from beginning of study to cut off date of interim analysis (25 months)
- Population
- All patients randomized onto study by cut off date of interim analysis
Source ClinicalTrials.gov
Trial
- Title
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
- NCT number
- NCT02979899
- Phases
- PHASE3
- Conditions
- Advanced Angiosarcoma
- Interventions
- TRC105, Votrient
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Results first posted
- 2020-05-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02979899?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02979899-69e3a058